Tax

Federal Tax (Deferred)

Vertex Pharmaceuticals Federal Tax (Deferred) remained flat by 0.0% to -$131.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 20.1%, from -$109.68M to -$131.75M. Over 2 years (FY 2023 to FY 2025), Federal Tax (Deferred) shows relatively stable performance with a -3.8% CAGR.

Analysis

StatementIncome Statement
SectionTax
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025

How to read this metric

An increase in deferred tax liabilities suggests future cash tax payments, while deferred tax assets may indicate future tax savings.

Detailed definition

The portion of the income tax provision that represents future tax liabilities or assets resulting from temporary differ...

Peer comparison

Standard accounting metric for all companies following GAAP or IFRS.

Metric ID: is_msft_deferred_federal_tax_expense

Historical Data

3 years
 FY'23FY'24FY'25
Value-$569.90M-$438.70M-$527.00M
YoY Change—+23.0%-20.1%
Range-$569.90M – -$438.70M
CAGR-3.8%
Avg YoY Growth+1.4%
Median YoY Growth+1.4%

Frequently Asked Questions

What is Vertex Pharmaceuticals's federal tax (deferred)?
Vertex Pharmaceuticals (VRTX) reported federal tax (deferred) of -$131.75M in Q4 2025.
How has Vertex Pharmaceuticals's federal tax (deferred) changed year-over-year?
Vertex Pharmaceuticals's federal tax (deferred) decreased by 20.1% year-over-year, from -$109.68M to -$131.75M.
What is the long-term trend for Vertex Pharmaceuticals's federal tax (deferred)?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's federal tax (deferred) has grown at a -3.8% compound annual growth rate (CAGR), from -$569.90M to -$527.00M.
What does federal tax (deferred) mean?
The portion of federal income tax expense that is deferred to future periods due to timing differences.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.